Intellectual Property Licensing
•217 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (217)
| Company | Market Cap | Price |
|---|---|---|
|
DIS
The Walt Disney Company
Disney monetizes its extensive IP portfolio via Intellectual Property Licensing agreements.
|
$187.49B |
$102.26
-1.94%
|
|
QCOM
QUALCOMM Incorporated
Intellectual Property Licensing accurately reflects QTL's long-term, high-margin IP licensing revenue model.
|
$176.20B |
$166.09
+1.71%
|
|
ARM
Arm Holdings plc American Depositary Shares
Arm's primary revenue is intellectual property licensing for chip designs.
|
$138.67B |
$135.62
+3.08%
|
|
SNPS
Synopsys, Inc.
The company licenses intellectual property (design IP) as a core revenue stream.
|
$60.26B |
$400.91
+3.23%
|
|
TTWO
Take-Two Interactive Software, Inc.
Intellectual property licensing of TTWO's game IP/assets to partners is a distinct license-based revenue stream.
|
$43.44B |
$238.20
+1.16%
|
|
TKO
TKO Group Holdings, Inc.
Intellectual property licensing as a broader category for IP monetization.
|
$35.33B |
$180.71
+1.43%
|
|
ERIC
Telefonaktiebolaget LM Ericsson (publ)
Intellectual Property Licensing represents a key monetization channel via IPR licensing of Ericsson's technology.
|
$31.44B |
$9.41
+0.16%
|
|
FSLR
First Solar, Inc.
Licensing and enforcement of intellectual property (TOPCon patent portfolio) with licensing revenue.
|
$26.80B |
$258.43
+3.41%
|
|
CRDO
Credo Technology Group Holding Ltd
The company also participates in IP licensing revenue, which maps to Intellectual Property Licensing.
|
$22.91B |
$148.52
+11.26%
|
|
RPRX
Royalty Pharma plc
Royalties arise from intellectual property licensing of biopharma assets.
|
$22.70B |
$39.45
+1.36%
|
|
XPEV
XPeng Inc.
Intellectual Property Licensing — IP licensing revenue from collaborations with Volkswagen.
|
$19.28B |
$20.91
+2.68%
|
|
GFS
GLOBALFOUNDRIES Inc.
GF's acquisition of MIPS adds IP licensing revenue through RISC-V processor IP and related software tools.
|
$18.78B |
$34.67
+2.00%
|
|
GWRE
Guidewire Software, Inc.
Intellectual Property Licensing as Guidewire licenses software/IP to customers.
|
$17.93B |
$210.59
-1.13%
|
|
WMG
Warner Music Group Corp.
WMG engages in intellectual property licensing related to its music catalogs and IP assets.
|
$16.00B |
$29.07
-5.28%
|
|
NWS
News Corporation
Intellectual property licensing of IP assets to partners in AI/content domains.
|
$14.51B |
$28.93
-0.26%
|
|
LYB
LyondellBasell Industries N.V.
LYB licenses polyolefin process technologies and sells catalysts, constituting intellectual property licensing activity.
|
$14.41B |
$44.79
-0.02%
|
|
ROIV
Roivant Sciences Ltd.
Genevant's LNP/IP licensing revenue supports Intellectual Property Licensing.
|
$13.81B |
$20.39
+0.84%
|
|
HAS
Hasbro, Inc.
Hasbro monetizes intellectual property through licensing arrangements across media, entertainment, and consumer products.
|
$11.11B |
$79.39
+0.23%
|
|
RMBS
Rambus Inc.
Derives revenue from Intellectual Property Licensing, including silicon IP cores (HBM4 IP, PCIe 7 IP).
|
$9.48B |
$92.28
+4.69%
|
|
IDCC
InterDigital, Inc.
InterDigital's core business is licensing its large patent portfolio (wireless, video, and AI technologies) to device makers and other partners, i.e., an Intellectual Property Licensing business.
|
$8.45B |
$343.37
+4.80%
|
|
SARO
StandardAero, Inc.
Licensing of engine platform IP (CF34) and related technology.
|
$8.27B |
$24.91
+0.67%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme licenses its MDASE technology and related hyaluronidase IP (i.e., IP Licensing) to partners.
|
$8.23B |
$72.08
+2.47%
|
|
QS
QuantumScape Corporation
QuantumScape monetizes its development through Intellectual Property Licensing, including licensing agreements and royalty arrangements with automotive partners.
|
$6.49B |
$11.81
+3.01%
|
|
DLB
Dolby Laboratories, Inc.
Dolby's core revenue is through licensing its intellectual property and patents (e.g., Atmos, Vision), which fits Intellectual Property Licensing.
|
$6.47B |
$66.89
-0.87%
|
|
MNSO
MINISO Group Holding Limited
MINISO emphasizes developing proprietary IP and licensing IP across markets, a key driver of growth.
|
$6.08B |
$19.24
-1.69%
|
|
OLED
Universal Display Corporation
Licensing revenue is a core business model, via Intellectual Property Licensing.
|
$5.41B |
$113.94
+0.18%
|
|
KBR
KBR, Inc.
KBR licenses proprietary process technologies (ammonia, plastics recycling, lithium extraction) to customers.
|
$5.19B |
$39.69
-1.56%
|
|
COGT
Cogent Biosciences, Inc.
Cogent engages in Intellectual Property Licensing via a license arrangement with Plexxikon for bezuclastinib, constituting Intellectual Property Licensing.
|
$5.14B |
$37.82
+2.88%
|
|
ALKS
Alkermes plc
Intellectual property licensing and royalty arrangements with Janssen Biotech and Biogen.
|
$4.72B |
$28.10
-1.78%
|
|
PI
Impinj, Inc.
NXP patent settlement licenses IP revenue; licensing is a direct revenue stream.
|
$4.47B |
$157.89
+2.81%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Ligand monetizes its proprietary technologies and licenses IP to pharma/biotech partners, generating royalty streams.
|
$3.90B |
$204.46
+2.63%
|
|
VICR
Vicor Corporation
Vicor actively licenses IP and has realized licensing settlements, a material revenue stream.
|
$3.79B |
$87.30
+3.47%
|
|
LCID
Lucid Group, Inc.
Intellectual Property Licensing; licensing Lucid's tech to Aston Martin and other OEM discussions.
|
$3.78B |
$12.55
+2.07%
|
|
CNTA
Centessa Pharmaceuticals plc
Exclusive license agreement for LockBody with Genmab constitutes intellectual property licensing activity.
|
$3.75B |
$28.89
+3.27%
|
|
KFY
Korn Ferry
Licensing of Korn Ferry's IP and proprietary intelligence/data assets.
|
$3.37B |
$64.32
-0.86%
|
|
FOLD
Amicus Therapeutics, Inc.
The company engages in licensing and IP-focused transactions (e.g., DMX-200 license and IP protections for Galafold), mapping to Intellectual Property Licensing.
|
$2.95B |
$9.84
+2.93%
|
|
IPAR
Inter Parfums, Inc.
Interparfums licenses intellectual property/assets (brands/fragrances) to third parties as a core revenue stream.
|
$2.59B |
$79.94
-0.83%
|
|
BB
BlackBerry Limited
BB licenses its intellectual property and AI/ML patents via the Licensing division, representing an IP licensing revenue stream.
|
$2.48B |
$4.17
-0.12%
|
|
CLVT
Clarivate Plc
Derwent IP data and related platforms involve Intellectual Property Licensing to customers.
|
$2.44B |
$3.44
+0.29%
|
|
BEAM
Beam Therapeutics Inc.
Beam licenses complementary gene editing technologies (e.g., prime editing, Cas12b, RNA base editing), constituting an Intellectual Property Licensing activity.
|
$2.25B |
$23.30
+4.91%
|
|
LION
Lionsgate Studios Corp.
Lionsgate licenses its intellectual property and related assets to third parties, contributing to its revenue through IP licensing.
|
$2.06B |
$7.21
+1.19%
|
|
TGI
Triumph Group, Inc.
Triumph leverages proprietary IP in its aftermarket and platform-specific components, aligning with IP Licensing themes.
|
$2.01B |
$26.01
|
|
PRKS
United Parks & Resorts Inc.
Engages in IP/licensing arrangements around its park brands and content, aligning with Intellectual Property Licensing.
|
$1.84B |
$33.85
+1.21%
|
|
WLYB
John Wiley & Sons, Inc.
Intellectual Property Licensing: licensing of IP/content to partners and AI/data licensing arrangements.
|
$1.79B |
$34.13
+1.58%
|
|
WBTN
WEBTOON Entertainment Inc. Common stock
Licensing of intellectual property/assets to partners (e.g., Disney/Marvel/Star Wars) for broader media expansion.
|
$1.78B |
$14.21
+4.45%
|
|
MESO
Mesoblast Limited
Intellectual property licensing and royalty income from collaborations (e.g., JCR, Takeda).
|
$1.77B |
$15.60
+1.50%
|
|
ZBIO
Zenas BioPharma, Inc.
Company engages in IP licensing and collaboration revenue with multiple partners.
|
$1.51B |
$37.21
+3.94%
|
|
PCT
PureCycle Technologies, Inc.
PureCycle licenses the dissolution purification technology from Procter & Gamble, constituting a core IP licensing facet of the business.
|
$1.49B |
$8.24
-0.54%
|
|
WINA
Winmark Corporation
Brand IP licensing of the resale brands aligns with intellectual property licensing.
|
$1.48B |
$416.48
-0.28%
|
|
FBYD
Falcon's Beyond Global, Inc. Class A Common Stock
Intellectual property licensing supports cross-channel monetization of IP assets.
|
$1.48B |
$13.28
+8.76%
|
|
ADEA
Adeia Inc.
Adeia's primary business model is Intellectual Property Licensing, licensing a large portfolio of patents and IP assets.
|
$1.32B |
$12.14
+0.83%
|
|
INBX
Inhibrx Biosciences, Inc.
License/IP assets licensing with third parties (Scithera) for non-dilutive funding potential.
|
$1.22B |
$80.08
-4.59%
|
|
RLAY
Relay Therapeutics, Inc.
Relay pursues intellectual property licensing and asset licensing (e.g., lirafugratinib licensing) as a business activity.
|
$1.17B |
$8.09
+19.42%
|
|
XNCR
Xencor, Inc.
Business relies on licensing XmAb technology to partners with royalty/milestone monetization.
|
$1.13B |
$16.64
+4.85%
|
|
ANAB
AnaptysBio, Inc.
Revenues include licensing and monetization of royalties related to external assets (IP licensing).
|
$1.11B |
$41.74
+5.38%
|
|
NVAX
Novavax, Inc.
Novavax monetizes its intellectual property through licensing and milestone/royalty arrangements with partners (e.g., Sanofi).
|
$1.05B |
$6.63
+2.47%
|
|
SLDP
Solid Power, Inc.
SLDP licenses its electrolyte technology and related cell manufacturing know-how to partners, fitting Intellectual Property Licensing.
|
$910.05M |
$5.03
+0.10%
|
|
LENZ
LENZ Therapeutics, Inc.
LENZ engages in intellectual property licensing with international deals (Greater China, Southeast Asia, Canada), forming a core IP licensing revenue and moat.
|
$843.11M |
$31.62
+6.97%
|
|
ABUS
Arbutus Biopharma Corporation
The company licenses its LNP technology and pursues IP litigation, making Intellectual Property Licensing a direct business line.
|
$826.22M |
$4.22
-2.09%
|
|
MNMD
Mind Medicine (MindMed) Inc.
Exclusive licensing of Catalent's Zydis ODT technology represents Intellectual Property Licensing.
|
$812.62M |
$11.64
+8.99%
|
|
RDW
Redwire Corporation
Space-derived intellectual property and licensing (e.g., crystal forms) align with 'Intellectual Property Licensing'.
|
$763.41M |
$5.38
+1.51%
|
|
SCHL
Scholastic Corporation
Intellectual property licensing of core franchises and characters beyond publishing.
|
$721.43M |
$28.72
-0.28%
|
|
SKYT
SkyWater Technology, Inc.
Intellectual property licensing could be a revenue stream tied to IP co-development with customers.
|
$672.53M |
$14.80
+6.02%
|
|
NPWR
NET Power Inc.
Net Power's business model centers on licensing its Net Power Cycle IP to partners for commercial deployment.
|
$545.87M |
$2.52
+1.41%
|
|
AIP
Arteris, Inc.
Arteris licenses NoC interconnect IP to semiconductor designers, making IP licensing a core revenue source.
|
$543.36M |
$13.36
+4.87%
|
|
LWLG
Lightwave Logic, Inc.
LWLG derives revenue from licensing its electro-optic polymer technology and providing technology transfers.
|
$532.00M |
$4.29
+4.38%
|
|
HCKT
The Hackett Group, Inc.
Intellectual Property Licensing – licensing of Gen AI platforms/IP to clients and partners via the JV and related engagements.
|
$499.59M |
$18.33
+0.94%
|
|
NRGV
Energy Vault Holdings, Inc.
Exclusive IP licensing revenue (B-Vault IP) fits Intellectual Property Licensing.
|
$487.18M |
$2.94
-2.49%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra engages in licensing of IP and out-licensing of pre-clinical assets; fits Intellectual Property Licensing.
|
$482.76M |
$8.69
+1.05%
|
|
RSVR
Reservoir Media, Inc.
Intellectual property licensing captures the broader IP licensing activity around music catalogs and related assets.
|
$478.58M |
$7.23
-0.96%
|
|
CEVA
CEVA, Inc.
CEVA's core business is IP licensing for DSPs, NPUs and wireless IP, making Intellectual Property Licensing a primary revenue source.
|
$453.76M |
$19.80
+4.18%
|
|
ADCT
ADC Therapeutics S.A.
The company derives license revenues and royalties from partnerships, fitting Intellectual Property Licensing.
|
$452.25M |
$4.33
+7.59%
|
|
CRNC
Cerence Inc.
Cerence licenses its AI/IP assets to customers and partners, aligning with intellectual property licensing themes.
|
$448.36M |
$10.72
+3.62%
|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 licensing and exclusive rights indicate Intellectual Property Licensing activity.
|
$447.84M |
$28.47
+5.13%
|
|
SIGA
SIGA Technologies, Inc.
SIGA licenses intellectual property (monoclonal antibodies) to advance its pipeline, fitting Intellectual Property Licensing.
|
$418.18M |
$5.98
+2.40%
|
|
PRTC
PureTech Health plc
Portfolio royalties and milestones from KarXT/Cobenfy fall under Intellectual Property Licensing.
|
$410.88M |
$16.29
+1.31%
|
|
BYRN
Byrna Technologies Inc.
LATAM divestiture into licensing/distribution suggests material IP licensing revenue.
|
$396.18M |
$17.25
-1.12%
|
|
GRVY
Gravity Co., Ltd.
Ragnarok IP licensing is a core monetization channel, enabling merchandise and cross-media licensing.
|
$392.89M |
$57.12
+1.03%
|
|
PHCI
Panamera Holdings Corporation
PHCI's binding LOI/license for Rain Cage's carbon conversion technology constitutes intellectual property licensing.
|
$384.10M |
$8.44
|
|
AMCX
AMC Networks Inc.
Licenses intellectual property across platforms, including IP libraries and franchises.
|
$370.93M |
$8.76
+2.40%
|
|
ZH
Zhihu Inc.
Intellectual property licensing for branded content and AI/IP assets.
|
$368.45M |
$3.98
-0.13%
|
|
VALU
Value Line, Inc.
Intellectual property licensing related to Value Line's proprietary research technology and rankings.
|
$347.31M |
$36.31
-1.63%
|
|
ACTG
Acacia Research Corporation
Company monetizes patented portfolios via licensing and enforcement, core IP licensing business.
|
$345.27M |
$3.65
+1.96%
|
|
CLLS
Cellectis S.A.
Cellectis licenses TALEN IP and related technologies (e.g., to Iovance), reflecting an IP licensing revenue/strategy.
|
$338.12M |
$5.25
+11.94%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
The company monetizes IP via licensing/royalties (e.g., MAVYRET royalties and related licensing actions), aligning with Intellectual Property Licensing.
|
$272.14M |
$13.55
+6.44%
|
|
XPER
Xperi Inc.
Intellectual Property Licensing is a core revenue and strategic lever for Xperi through its technology IP.
|
$262.76M |
$5.79
+1.94%
|
|
QSG
QuantaSing Group Ltd
The company develops IPs and monetizes them through licensing arrangements, including exclusive and nonexclusive IP licenses.
|
$256.41M |
$5.81
+18.81%
|
|
DVLT
Datavault AI Inc.
DVLT monetizes its proprietary IP through licensing of its patented data valuation and monetization technologies.
|
$249.12M |
$2.42
-5.10%
|
|
EDIT
Editas Medicine, Inc.
Intellectual Property Licensing: monetization of IP through licensing deals with Vertex and DRI.
|
$217.61M |
$2.48
+2.69%
|
|
OABI
OmniAb, Inc.
OmniAb's business model centers on licensing its Biological Intelligence platforms and IP to partners, supported by milestone and royalty economics.
|
$217.18M |
$1.78
+0.85%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet engages in licensing of its denifanstat IP with Ascletis for China, indicating an IP licensing business activity.
|
$216.92M |
$6.61
-0.90%
|
|
BDTX
Black Diamond Therapeutics, Inc.
Licensing of BDTX-4933 to Servier constitutes Intellectual Property Licensing activity.
|
$216.35M |
$3.87
+1.71%
|
|
INV
Innventure, Inc.
Innventure licenses technologies and IP from MNCs, making Intellectual Property Licensing a core business activity.
|
$209.59M |
$4.47
+5.79%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
Strategic review emphasizes licensing IP/assets and monetizing IP, fitting Intellectual Property Licensing.
|
$206.13M |
$4.47
|
|
SKYX
SKYX Platforms Corp.
Intellectual property licensing for SKYX's plug-and-play technology (licensing revenue).
|
$200.60M |
$2.00
+11.39%
|
|
DERM
Journey Medical Corporation
Journey Medical monetizes its intellectual property via licensing/out-licensing deals (e.g., Emrosi and other assets).
|
$181.86M |
$7.46
-0.07%
|
|
SRM
SRM Entertainment, Inc.
SRM engages in IP licensing/transfer of IP assets to create products, aligning with Intellectual Property Licensing.
|
$177.61M |
$10.30
|
|
GCL
GCL Global Holdings Ltd Ordinary Shares
GCL monetizes game IP via publishing and licensing arrangements, including developing and licensing IP.
|
$171.67M |
$1.36
|
|
MRAM
Everspin Technologies, Inc.
Revenue from licensing IP and IP monetization, a material revenue stream for the company.
|
$169.69M |
$7.70
+2.60%
|
|
PLBY
Playboy, Inc.
Intellectual property licensing of Playboy assets to partners/licensees is a direct business line.
|
$162.64M |
$1.78
+4.39%
|
Showing page 1 of 3 (217 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
